Clinical trial
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
NCT00331643 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00331643 |
|---|---|
| Title | Ixabepilone in Treating Young Patients With Refractory Solid Tumors |
| Official title | Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Synovial Sarcoma, Embryonal Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and 3 more |
| Intervention type | Drug |
| Interventions | ixabepilone |
| Enrollment | 120 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Jun 1, 2009 |
| First posted | May 31, 2006 |
| Last update posted | Nov 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: